

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Pharmacology

ESPS manuscript NO: 33515

Title: Tenofovir induced severe thrombocytopenia

Reviewer's code: 00503345

Reviewer's country:Canada

Science editor: Fang-Fang Ji

Date sent for review: 2017-02-15 18:58

Date reviewed:2017-02-19 01:29

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	GoogleSearch:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors report on a case of thrombocytopenia following introduction of prophylactic tenofovir DF. Adverse effects of antiviral therapies include rare events of immune thrombocytopenia. Though not reported in the literature, tenofovir has been suspected to cause thrombocytopenia and a few individuals taking tenofovir DF reported thrombocytopenia to the FDA. This report highlights a rare case of thrombocytopenia after switching therapy to tenofovir DF. This information will be useful but I would suggest the authors to strengthen a bit the discussion and commenting the published abstract/paper cited below. DeJesus E, Sharma S, Corales R, Ebrahimi R, Fisher A, Flaherty J. Impact of switching virologically suppressed, HIV-infected patients from fixed-dose zidovudine/lamivudine (CBV) to fixed-dose tenofovir DF/emtricitabine (TVD). In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, United Kingdom. Abstract P53. Benjamin T Schleenvoigt, John P Fobiwe1, Peter M Keller, Stefan Hagel and Mathias W Pletz. HIV post exposure prophylaxis induced bicytopenia: a case report. Aids Res Ther 2014. 11 :11

Author's reply

Dear reviewer,

Thanks for your detailed review. As per your suggestions, the mentioned references have been incorporated in the text. The text has been modified slightly to strengthen it

Regards

The authors

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Pharmacology
ESPS manuscript NO: 33515
Title: Tenofovir induced severe thrombocytopenia
Reviewer's code: 00504345
Reviewer's country: Bulgaria
Science editor: Fang-Fang Ji
Date sent for review: 2017-02-15 18:58
Date reviewed: 2017-03-02 00:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	GoogleSearch:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

1. The choice of Tenofovir for the prophylaxis of hepatitis B virus infection in patient with liver transplantation and on Tacrolimus immunosuppressive regime was not good decision from the point of view of GCP. Both drugs have heavy side effects on kidneys function! 2. "tenofovir induced thrombocytopenia has not be described in the world literature". This statement is not true. Thrombocytopenia after tenofovir although rare side effect is described in many reports, including FDA safety reports.

Dear reviewer,

Thanks for your detailed assessment of our case report. Both tacrolimus and tenofovir have renal side effects. However, in the described case, renal function was stable at the ime of introduction of tenofovir. Tenofovir was considered for management due to its potent antiviral activity. The statement . "tenofovir induced thrombocytopenia has not be described in the world literature" has been changed

Regards

The authors